Exelixis Announces February 21st Webcast of Fourth Quarter and Full Year 2012 Financial Results Conference Call
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Exelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full
year 2012 financial results on Thursday, February 21, 2013 after the
markets close. The announcement will be followed by a live webcast at
5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management
will discuss the Company’s financial results, financial outlook, and
development program and plans for cabozantinib, and also provide a
general business update. The webcast may be accessed in the Event
Calendar page under Investors & Media at www.exelixis.com.
An archived replay of the webcast will be available on the Event
Calendar page under Investors & Media at www.exelixis.com
and via phone until 11:59 p.m. PST on March 21, 2013. Access numbers for
the phone replay are: 888-286-8010 (domestic) and 617-801-6888
(international); the passcode is 32648982.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on COMETRIQ™
(cabozantinib). Exelixis has also established a portfolio of other novel
compounds that it believes have the potential to address serious unmet
medical needs, many of which are being advanced by partners as part of
collaborations. For more information, please visit the company's web
site at www.exelixis.com.
Exelixis, Inc. Charles Butler, 650-837-7277 Vice President,
Investor Relations and Corporate Communications cbutler@exelixis.com
Press Release $EXEL Exelixis, Inc.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full year 2012 financial results on Thursday, February 21, 2013 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss the Company’s financial results, financial outlook, and development program and plans for cabozantinib, and also provide a general business update. The webcast may be accessed in the Event Calendar page under Investors & Media at www.exelixis.com.
An archived replay of the webcast will be available on the Event Calendar page under Investors & Media at www.exelixis.com and via phone until 11:59 p.m. PST on March 21, 2013. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 32648982.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ™ (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
cbutler@exelixis.com
Source: Exelixis, Inc.